Antiobesity effect of eicosapentaenoic acid in high-fat/high-sucrose diet-induced obesity: Importance of hepatic lipogenesis

Ayumi Sato, Hiroyuki Kawano, Tatsuto Notsu, Masahiko Ohta, Masanori Nakakuki, Kiyoshi Mizuguchi, Michiko Itoh, Takayoshi Suganami, Yoshihiro Ogawa

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

OBJECTIVE - Given the pleiotropic effect of eicosapentaenoic acid (EPA), it is interesting to know whether EPA is capable of improving obesity. Here we examined the anti-obesity effect of EPA in mice with two distinct models of obesity. RESEARCH DESIGN AND METHODS - Male C57BL/6J mice were fed a high-fat/high-sucrose diet (25.0% [w/w] fat, 32.5% [w/w] sucrose) (HF/HS group) or a high-fat diet (38.1% [w/w] fat, 8.5% [w/w] sucrose) (HF group) for 4-20 weeks. A total of 5% EPA was administered by partially substituting EPA for fat in the HF/HS + EPA and HF + EPA groups. RESULTS - Both the HF/HS and HF groups similarly developed obesity. EPA treatment strongly suppresses body weight gain and obesity-related hyperglycemia and hyperinsulinemia in HF/HS-fed mice (HF/HS + EPA group), where hepatic triglyceride content and lipogenic enzymes are increased. There is no appreciable effect of EPA on body weight in HF-fed mice (HF + EPA group) without enhanced expression of hepatic lipogenic enzymes. Moreover, EPA is capable of reducing hepatic triglyceride secretion and changing VLDL fatty acid composition in the HF/HS group. By indirect calorimetry analysis, we also found that EPA is capable of increasing energy consumption in the HF/HS + EPA group. CONCLUSIONS - This study is the first demonstration that the anti-obesity effect of EPA in HF/HS-induced obesity is associated with the suppression of hepatic lipogenesis and steatosis. Because the metabolic syndrome is often associated with hepatic lipogenesis and steatosis, the data suggest that EPA is suited for treatment of the metabolic syndrome.

Original languageEnglish
Pages (from-to)2495-2504
Number of pages10
JournalDiabetes
Volume59
Issue number10
DOIs
Publication statusPublished - Oct 1 2010
Externally publishedYes

Fingerprint

Lipogenesis
Eicosapentaenoic Acid
High Fat Diet
Sucrose
Obesity
Liver
Fats
Triglycerides
Body Weight
Indirect Calorimetry
Hyperinsulinism
Enzymes
Inbred C57BL Mouse

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Antiobesity effect of eicosapentaenoic acid in high-fat/high-sucrose diet-induced obesity : Importance of hepatic lipogenesis. / Sato, Ayumi; Kawano, Hiroyuki; Notsu, Tatsuto; Ohta, Masahiko; Nakakuki, Masanori; Mizuguchi, Kiyoshi; Itoh, Michiko; Suganami, Takayoshi; Ogawa, Yoshihiro.

In: Diabetes, Vol. 59, No. 10, 01.10.2010, p. 2495-2504.

Research output: Contribution to journalArticle

Sato, A, Kawano, H, Notsu, T, Ohta, M, Nakakuki, M, Mizuguchi, K, Itoh, M, Suganami, T & Ogawa, Y 2010, 'Antiobesity effect of eicosapentaenoic acid in high-fat/high-sucrose diet-induced obesity: Importance of hepatic lipogenesis', Diabetes, vol. 59, no. 10, pp. 2495-2504. https://doi.org/10.2337/db09-1554
Sato, Ayumi ; Kawano, Hiroyuki ; Notsu, Tatsuto ; Ohta, Masahiko ; Nakakuki, Masanori ; Mizuguchi, Kiyoshi ; Itoh, Michiko ; Suganami, Takayoshi ; Ogawa, Yoshihiro. / Antiobesity effect of eicosapentaenoic acid in high-fat/high-sucrose diet-induced obesity : Importance of hepatic lipogenesis. In: Diabetes. 2010 ; Vol. 59, No. 10. pp. 2495-2504.
@article{cc6c6c0967ed45df9272986df7fba57b,
title = "Antiobesity effect of eicosapentaenoic acid in high-fat/high-sucrose diet-induced obesity: Importance of hepatic lipogenesis",
abstract = "OBJECTIVE - Given the pleiotropic effect of eicosapentaenoic acid (EPA), it is interesting to know whether EPA is capable of improving obesity. Here we examined the anti-obesity effect of EPA in mice with two distinct models of obesity. RESEARCH DESIGN AND METHODS - Male C57BL/6J mice were fed a high-fat/high-sucrose diet (25.0{\%} [w/w] fat, 32.5{\%} [w/w] sucrose) (HF/HS group) or a high-fat diet (38.1{\%} [w/w] fat, 8.5{\%} [w/w] sucrose) (HF group) for 4-20 weeks. A total of 5{\%} EPA was administered by partially substituting EPA for fat in the HF/HS + EPA and HF + EPA groups. RESULTS - Both the HF/HS and HF groups similarly developed obesity. EPA treatment strongly suppresses body weight gain and obesity-related hyperglycemia and hyperinsulinemia in HF/HS-fed mice (HF/HS + EPA group), where hepatic triglyceride content and lipogenic enzymes are increased. There is no appreciable effect of EPA on body weight in HF-fed mice (HF + EPA group) without enhanced expression of hepatic lipogenic enzymes. Moreover, EPA is capable of reducing hepatic triglyceride secretion and changing VLDL fatty acid composition in the HF/HS group. By indirect calorimetry analysis, we also found that EPA is capable of increasing energy consumption in the HF/HS + EPA group. CONCLUSIONS - This study is the first demonstration that the anti-obesity effect of EPA in HF/HS-induced obesity is associated with the suppression of hepatic lipogenesis and steatosis. Because the metabolic syndrome is often associated with hepatic lipogenesis and steatosis, the data suggest that EPA is suited for treatment of the metabolic syndrome.",
author = "Ayumi Sato and Hiroyuki Kawano and Tatsuto Notsu and Masahiko Ohta and Masanori Nakakuki and Kiyoshi Mizuguchi and Michiko Itoh and Takayoshi Suganami and Yoshihiro Ogawa",
year = "2010",
month = "10",
day = "1",
doi = "10.2337/db09-1554",
language = "English",
volume = "59",
pages = "2495--2504",
journal = "Diabetes",
issn = "0012-1797",
publisher = "医学出版",
number = "10",

}

TY - JOUR

T1 - Antiobesity effect of eicosapentaenoic acid in high-fat/high-sucrose diet-induced obesity

T2 - Importance of hepatic lipogenesis

AU - Sato, Ayumi

AU - Kawano, Hiroyuki

AU - Notsu, Tatsuto

AU - Ohta, Masahiko

AU - Nakakuki, Masanori

AU - Mizuguchi, Kiyoshi

AU - Itoh, Michiko

AU - Suganami, Takayoshi

AU - Ogawa, Yoshihiro

PY - 2010/10/1

Y1 - 2010/10/1

N2 - OBJECTIVE - Given the pleiotropic effect of eicosapentaenoic acid (EPA), it is interesting to know whether EPA is capable of improving obesity. Here we examined the anti-obesity effect of EPA in mice with two distinct models of obesity. RESEARCH DESIGN AND METHODS - Male C57BL/6J mice were fed a high-fat/high-sucrose diet (25.0% [w/w] fat, 32.5% [w/w] sucrose) (HF/HS group) or a high-fat diet (38.1% [w/w] fat, 8.5% [w/w] sucrose) (HF group) for 4-20 weeks. A total of 5% EPA was administered by partially substituting EPA for fat in the HF/HS + EPA and HF + EPA groups. RESULTS - Both the HF/HS and HF groups similarly developed obesity. EPA treatment strongly suppresses body weight gain and obesity-related hyperglycemia and hyperinsulinemia in HF/HS-fed mice (HF/HS + EPA group), where hepatic triglyceride content and lipogenic enzymes are increased. There is no appreciable effect of EPA on body weight in HF-fed mice (HF + EPA group) without enhanced expression of hepatic lipogenic enzymes. Moreover, EPA is capable of reducing hepatic triglyceride secretion and changing VLDL fatty acid composition in the HF/HS group. By indirect calorimetry analysis, we also found that EPA is capable of increasing energy consumption in the HF/HS + EPA group. CONCLUSIONS - This study is the first demonstration that the anti-obesity effect of EPA in HF/HS-induced obesity is associated with the suppression of hepatic lipogenesis and steatosis. Because the metabolic syndrome is often associated with hepatic lipogenesis and steatosis, the data suggest that EPA is suited for treatment of the metabolic syndrome.

AB - OBJECTIVE - Given the pleiotropic effect of eicosapentaenoic acid (EPA), it is interesting to know whether EPA is capable of improving obesity. Here we examined the anti-obesity effect of EPA in mice with two distinct models of obesity. RESEARCH DESIGN AND METHODS - Male C57BL/6J mice were fed a high-fat/high-sucrose diet (25.0% [w/w] fat, 32.5% [w/w] sucrose) (HF/HS group) or a high-fat diet (38.1% [w/w] fat, 8.5% [w/w] sucrose) (HF group) for 4-20 weeks. A total of 5% EPA was administered by partially substituting EPA for fat in the HF/HS + EPA and HF + EPA groups. RESULTS - Both the HF/HS and HF groups similarly developed obesity. EPA treatment strongly suppresses body weight gain and obesity-related hyperglycemia and hyperinsulinemia in HF/HS-fed mice (HF/HS + EPA group), where hepatic triglyceride content and lipogenic enzymes are increased. There is no appreciable effect of EPA on body weight in HF-fed mice (HF + EPA group) without enhanced expression of hepatic lipogenic enzymes. Moreover, EPA is capable of reducing hepatic triglyceride secretion and changing VLDL fatty acid composition in the HF/HS group. By indirect calorimetry analysis, we also found that EPA is capable of increasing energy consumption in the HF/HS + EPA group. CONCLUSIONS - This study is the first demonstration that the anti-obesity effect of EPA in HF/HS-induced obesity is associated with the suppression of hepatic lipogenesis and steatosis. Because the metabolic syndrome is often associated with hepatic lipogenesis and steatosis, the data suggest that EPA is suited for treatment of the metabolic syndrome.

UR - http://www.scopus.com/inward/record.url?scp=77957606885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957606885&partnerID=8YFLogxK

U2 - 10.2337/db09-1554

DO - 10.2337/db09-1554

M3 - Article

C2 - 20682690

AN - SCOPUS:77957606885

VL - 59

SP - 2495

EP - 2504

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 10

ER -